Stocks · News reference
Filed: 2026-09-29 AccNo: 0001193125-26-407555 Size: 184 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lexeo Therapeutics, Inc. will present data from its cardiovascular and neurological genetic disease programs at the American Heart Association (AHA) Scientific Sessions 2026 and the International Congress for Ataxia Research (ICAR) 2026.
Lexeo Therapeutics announced an educational investor event on October 21, 2026, featuring discussions on clinical endpoints and outcome measures for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM). The event will include Lexeo's Chief Medical Officer and a specialist from Cleveland Clinic discussing the clinical significance of key assessments and treatment response evaluation for this genetic heart disease.
Lexeo Therapeutics, a clinical-stage biotech company, announced it will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is focused on developing genetic disease treatments, including LX2006 for Friedreich ataxia and LX2020 for arrhythmogenic cardiomyopathy.
Lexeo Therapeutics announced that its abstract for LX2006, an AAV-based gene therapy for Friedreich ataxia, has been accepted for oral presentation at the MDS 2026 Congress in Seoul. The presentation will highlight early stabilization or improvement in mFARS scores in LX2006-treated participants compared to propensity-matched controls, along with new subscore analyses. LX2006 has received multiple FDA designations including Breakthrough Therapy and Orphan Drug status.
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.